Adalvo Puts GLP-2 Agonist Teduglutide In The Crosshairs With ‘Day-1’ Filing
Marketed As Revestive, Treatment For Short Bowel Syndrome Backed By NICE
Executive Summary
Adalvo will look to add to its growing portfolio in Europe, expanding in rare disease treatments, after filing for a generic version of Takeda’s Revestive (teduglutide) on ‘day-1’ following the expiry of data exclusivity.